New drug combo aims to outsmart pancreatic cancer before surgery
NCT ID NCT06203821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial will test whether adding the study drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 people with resectable pancreatic cancer will receive the combination, and researchers will look for signs that the tumor becomes less aggressive. The goal is to see if this approach is safe and might help prevent the cancer from coming back or spreading.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NP137 (a study drug) plus FOLFIRINOX chemotherapy
What this could lead to
If it works, this could point toward a new treatment approach for pancreatic cancer that may help control the disease and reduce the chance of it spreading.
What could go wrong
This is a very early Phase 1 trial with only 25 people, so it is primarily testing safety and feasibility. The drug may not work as hoped, and side effects from the combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
Rochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact